InMed Pharmaceuticals Inc.
INMNASDAQHealthcare● Active
$1.54
$-0.04(-2.53%)
Market Cap$2787286
P/E Ratio—
52W High$5.5
52W Low$0.575
InMed Pharmaceuticals Inc. (INM) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
INM · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 6, 2026EPS Actual
-$0.69
Est. -$94.44 · +99.3%
Revenue
$0.00B
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 6, 2026
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
INM reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Sep 18, 2026 | -$94.44 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 6, 2026 | -$94.44 | -$0.69 | +99.3% | $0.00B | — | — |
| — Q1 FY2026 | Feb 11, 2026 | — | -$0.51 | — | $0.00B | — | — |
| — Q4 FY2025 | Nov 6, 2025 | — | -$0.44 | — | $0.00B | — | — |
| — Q3 FY2025 | Sep 23, 2025 | — | -$3.80 | — | $0.00B | — | — |
| — Q2 FY2025 | May 12, 2025 | — | -$1.94 | — | $0.00B | — | — |
| — Q1 FY2025 | Feb 12, 2025 | — | -$3.64 | — | $0.77B | — | — |
| — Q4 FY2024 | Nov 14, 2024 | — | -$54.20 | — | $0.00B | — | — |
Q3 FY2026
Sep 18, 2026
EPS Actual
—
EPS Est.
-$94.44
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 6, 2026Beat
EPS Actual
-$0.69
EPS Est.
-$94.44
EPS Surpr.
+99.3%
Revenue
$0.00B
Q1 FY2026
Feb 11, 2026
EPS Actual
-$0.51
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q4 FY2025
Nov 6, 2025
EPS Actual
-$0.44
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q3 FY2025
Sep 23, 2025
EPS Actual
-$3.80
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q2 FY2025
May 12, 2025
EPS Actual
-$1.94
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q1 FY2025
Feb 12, 2025
EPS Actual
-$3.64
EPS Est.
—
EPS Surpr.
—
Revenue
$0.77B
Q4 FY2024
Nov 14, 2024
EPS Actual
-$54.20
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2029 | $0.00 | $0.00 | $0.00 | 0 |
| Q2 FY2029 | $0.00 | $0.00 | $0.00 | 0 |
| Q1 FY2029 | $0.00 | $0.00 | $0.00 | 0 |
| Q4 FY2028 | $0.00 | $0.00 | $0.00 | 0 |
| Q3 FY2028 | $-85.00 | $-85.00 | $-85.00 | 1 |
| Q2 FY2028 | $-90.00 | $-90.00 | $-90.00 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2029 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2029 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2029 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 6, 2026 | +99.3% | $0.74 | $0.73 | -1.84% |
| — Q1 FY2026 | Feb 11, 2026 | — | $1.00 | $0.99 | -1.00% |
| — Q4 FY2025 | Nov 6, 2025 | — | $1.73 | $1.71 | -1.16% |
| — Q3 FY2025 | Sep 23, 2025 | — | $2.27 | $2.14 | -5.73% |
| — Q2 FY2025 | May 12, 2025 | — | $2.35 | $2.28 | -2.98% |
| — Q1 FY2025 | Feb 12, 2025 | — | $3.08 | $3.20 | +3.90% |
| — Q4 FY2024 | Nov 14, 2024 | — | $4.65 | $5.08 | +9.25% |
| — Q3 FY2024 | Sep 27, 2024 | — | $4.64 | $4.64 | +0.00% |
Q2 FY2026-1.84%
Report Date
May 6, 2026
EPS Beat/Miss
+99.3%
Price Before
$0.74
Price After
$0.73
Q1 FY2026-1.00%
Report Date
Feb 11, 2026
EPS Beat/Miss
—
Price Before
$1.00
Price After
$0.99
Q4 FY2025-1.16%
Report Date
Nov 6, 2025
EPS Beat/Miss
—
Price Before
$1.73
Price After
$1.71
Q3 FY2025-5.73%
Report Date
Sep 23, 2025
EPS Beat/Miss
—
Price Before
$2.27
Price After
$2.14
Q2 FY2025-2.98%
Report Date
May 12, 2025
EPS Beat/Miss
—
Price Before
$2.35
Price After
$2.28
Q1 FY2025+3.90%
Report Date
Feb 12, 2025
EPS Beat/Miss
—
Price Before
$3.08
Price After
$3.20
Q4 FY2024+9.25%
Report Date
Nov 14, 2024
EPS Beat/Miss
—
Price Before
$4.65
Price After
$5.08
Q3 FY2024+0.00%
Report Date
Sep 27, 2024
EPS Beat/Miss
—
Price Before
$4.64
Price After
$4.64
Avg Beat Reaction-1.84%
Beat Rate1 / 8 quarters
Largest Move+9.25% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: INM ends December
InMed Pharmaceuticals Inc. (INM) most recently reported earnings on May 6, 2026 for Q2 FY2026, posting EPS of $-0.69 — beating the analyst consensus of $-94.44 by +99.3%. The next INM earnings date is expected around September 1, 2026.
Each quarter, investors track INM earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. INM revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
INM's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
INM earnings · 5 questionsInMed Pharmaceuticals Inc.'s next earnings report is expected around September 1, 2026. INM typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; INM historically reports after market close (AMC).
INM earnings datewhen is INM earningsINM next earnings datewhen does INM report earningsINM earnings calendar
▸ Source: FMP · InMed Pharmaceuticals Inc. SEC filings · US GAAP · InMed Pharmaceuticals Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026